ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB
CYTB323A12101
Phase 2 small_molecule active
Quick answer
ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB for High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active